Regulated cell death pathways in cardiomyopathy

被引:0
作者
Shu-yuan Sheng
Jia-min Li
Xin-yang Hu
Yibin Wang
机构
[1] Zhejiang University School of Medicine,Department of Cardiology
[2] Second Affiliated Hospital,Signature Program in Cardiovascular and Metabolic Diseases
[3] DukeNUS Medical School and National Heart Center of Singapore,undefined
来源
Acta Pharmacologica Sinica | 2023年 / 44卷
关键词
cell death; cardiomyopathy; cell signaling;
D O I
暂无
中图分类号
学科分类号
摘要
Heart disease is a worldwide health menace. Both intractable primary and secondary cardiomyopathies contribute to malignant cardiac dysfunction and mortality. One of the key cellular processes associated with cardiomyopathy is cardiomyocyte death. Cardiomyocytes are terminally differentiated cells with very limited regenerative capacity. Various insults can lead to irreversible damage of cardiomyocytes, contributing to progression of cardiac dysfunction. Accumulating evidence indicates that majority of cardiomyocyte death is executed by regulating molecular pathways, including apoptosis, ferroptosis, autophagy, pyroptosis, and necroptosis. Importantly, these forms of regulated cell death (RCD) are cardinal features in the pathogenesis of various cardiomyopathies, including dilated cardiomyopathy, diabetic cardiomyopathy, sepsis-induced cardiomyopathy, and drug-induced cardiomyopathy. The relevance between abnormity of RCD with adverse outcome of cardiomyopathy has been unequivocally evident. Therefore, there is an urgent need to uncover the molecular and cellular mechanisms for RCD in order to better understand the pathogenesis of cardiomyopathies. In this review, we summarize the latest progress from studies on RCD pathways in cardiomyocytes in context of the pathogenesis of cardiomyopathies, with particular emphasis on apoptosis, necroptosis, ferroptosis, autophagy, and pyroptosis. We also elaborate the crosstalk among various forms of RCD in pathologically stressed myocardium and the prospects of therapeutic applications targeted to various cell death pathways.
引用
收藏
页码:1521 / 1535
页数:14
相关论文
共 1128 条
  • [1] McKenna WJ(2017)Classification, epidemiology, and global burden of cardiomyopathies Circ Res 121 722-30
  • [2] Maron BJ(2020)The Public Health Burden of Cardiomyopathies: insights from a Nationwide Inpatient Study J Clin Med 9 920-33
  • [3] Thiene G(2021)Recent findings related to cardiomyopathy and genetics Int J Mol Sci 22 15222-34
  • [4] Lannou S(2014)2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC) Eur Heart J 35 2733-79
  • [5] Mansencal N(2016)First experience with percutaneous mitral valve plication as primary therapy for symptomatic obstructive hypertrophic cardiomyopathy J Am Coll Cardiol 67 2811-8
  • [6] Couchoud C(2017)Correction of a pathogenic gene mutation in human embryos Nature 548 413-9
  • [7] Lassalle M(2015)Genetic advances in sarcomeric cardiomyopathies: state of the art Cardiovasc Res 105 397-408
  • [8] Dubourg O(2019)Novel therapies for prevention and early treatment of cardiomyopathies Circ Res 124 1536-50
  • [9] Stengel B(2022)Programming inflammatory cell death for therapy Pharmacol Ther 232 108010-54
  • [10] Yamada T(2022)The evolution of regulated cell death pathways in animals and their evasion by pathogens Physiol Rev 102 411-48